Tn MUC1 CAR T-cell therapy / Gilead - LARVOL DELTA

CART-TnMUC1-01: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers (clinicaltrials.gov) - P1 | N=16 | Terminated | Sponsor: Tmunity Therapeutics | N=112 ➔ 16 | Trial completion date: Oct 2036 ➔ Dec 2022 | Active, not recruiting ➔ Terminated; The sponsor finds the risk/benefit analysis unfavorable and has terminated the study.

CAR T-Cell Therapy • Enrollment change • Metastases • Trial completion date • Trial termination • Breast Cancer • Fallopian Tube Cancer • Gastrointestinal Cancer • Hematological Malignancies • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • HER-2 • MUC16

CART-TnMUC1-01: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers (clinicaltrials.gov) - P1 | N=112 | Active, not recruiting | Sponsor: Tmunity Therapeutics | Recruiting ➔ Active, not recruiting

CAR T-Cell Therapy • Enrollment closed • Breast Cancer • Fallopian Tube Cancer • Gastrointestinal Cancer • Hematological Malignancies • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • HER-2 • MUC16

[VIRTUAL] Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors. (ASCO 2021) - P1 | "This is the first report of a novel CART-TnMUC1 construct containing a CD2 co-stimulatory domain that has been used in clinical trials for the treatment of refractory solid-tumor malignancies . While the study is still early in dose-escalation having completed only 2 of 6 planned dose levels there is no evidence of safety concerns or on-target/off-tumor toxicity . Additional safety, efficacy and biomarker data is currently being reviewed and will be presented."

CAR T-Cell Therapy • Clinical • P1 data • Anemia • Breast Cancer • Fatigue • Gastrointestinal Cancer • Hematological Disorders • Hepatology • Immune Modulation • Inflammation • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pain • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • CD2 • CD8 • MUC1

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers (clinicaltrials.gov) - P1; N=80; Not yet recruiting; Sponsor: Tmunity Therapeutics

Clinical • New P1 trial • Breast Cancer • Fallopian Tube Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Thoracic Cancer • Triple Negative Breast Cancer • HER-2 • MUC16

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers (clinicaltrials.gov) - P1; N=80; Active, not recruiting; Sponsor: Tmunity Therapeutics; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Breast Cancer • Fallopian Tube Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Thoracic Cancer • Triple Negative Breast Cancer • HER-2 • MUC16

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers (clinicaltrials.gov) - P1; N=80; Recruiting; Sponsor: Tmunity Therapeutics; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Breast Cancer • Fallopian Tube Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Thoracic Cancer • Triple Negative Breast Cancer • HER-2 • MUC16

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers (clinicaltrials.gov) - P1; N=112; Recruiting; Sponsor: Tmunity Therapeutics; Active, not recruiting ➔ Recruiting; N=80 ➔ 112; Trial completion date: Jul 2034 ➔ Oct 2036

Clinical • Enrollment change • Enrollment open • Trial completion date • Breast Cancer • Fallopian Tube Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • Thoracic Cancer • Triple Negative Breast Cancer • HER-2 • MUC16

Tn MUC1 CAR T-cell therapy: Data from P1 trial (NCT04025216) for solid tumors in H2 2021 (39th Annual J.P. Morgan Healthcare Conference (Virtual Meeting), Tmunity Therapeutics)

P1 data • Non Small Cell Lung Cancer • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer

Tn MUC1 CAR T-cell therapy: Data from P1 trial (NCT04025216) for solid tumors in H2 2021 (39th Annual J.P. Morgan Healthcare Conference (Virtual Meeting), Tmunity Therapeutics)

P1 data • Non Small Cell Lung Cancer • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer

Tmunity announces first patient dosed in phase 1 clinical trial with CART-TnMUC1 (Businesswire) - “Tmunity Therapeutics, Inc…announced that it has dosed the first patient in its Phase 1 CART-TnMUC1-01 clinical trial with the Tn/STn glycoform of mucin 1 (TnMUC1) chimeric antigen receptor T-cell (CAR-T) therapy in patients with TnMUC1-positive advanced cancers.”

Enrollment open